Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug–drug interactions in medical intensive care patients.
Approach to Improving Safety
Setting of Care
This study found that having a clinical pharmacist participate in daily rounds reduced the number of clinically important drug–drug interactions (DDIs) after therapy modification. Lower numbers of DDIs were also associated with shorter lengths of stay, suggesting a potential business case for greater pharmacist involvement in this patient population.